Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $594.6 million.

  • Neurocrine Biosciences' Operating Expenses rose 2242.12% to $594.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 2558.27%. This contributed to the annual value of $2.2 billion for FY2025, which is 2558.27% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Operating Expenses of $594.6 million as of Q4 2025, which was up 2242.12% from $555.9 million recorded in Q3 2025.
  • Neurocrine Biosciences' Operating Expenses' 5-year high stood at $594.6 million during Q4 2025, with a 5-year trough of $205.1 million in Q1 2021.
  • Moreover, its 4-year median value for Operating Expenses was $438.3 million (2024), whereas its average is $423.0 million.
  • Data for Neurocrine Biosciences' Operating Expenses shows a peak YoY increase of 3310.5% (in 2024) and a maximum YoY decrease of 2218.48% (in 2024) over the last 5 years.
  • Neurocrine Biosciences' Operating Expenses (Quarter) stood at $251.5 million in 2021, then soared by 45.09% to $364.9 million in 2023, then surged by 33.1% to $485.7 million in 2024, then rose by 22.42% to $594.6 million in 2025.
  • Its Operating Expenses was $594.6 million in Q4 2025, compared to $555.9 million in Q3 2025 and $541.9 million in Q2 2025.